Spanish Ferrer SA pays €122.5m for ALS candidate
Spanish Ferrer Internacional, SA has aquired the ex-US rights to VRG50635 from Verge Genomics Inc to commercialise the oral Phase I experimental ALS treatment.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1163 entries already.
Entries by Thomas Gabrielczyk
Novo Nordisk to acquire Cardior Pharmaceuticals
/in News/by Thomas GabrielczykNovo Nordisk is set to acquire German miRNA blocker specialist Cardior Pharmaceuticals GmbH for up to €1.025bn including milestone payments.
NDM Pharma provides POC for NMD670
/in News/by Thomas GabrielczykResearchers at NDM Pharma A/S and Aarhus University have demonstrated that their oral CIC-1 blocker NMD670 restores crosstalk between neurons and muscles in Myasthenia gravis.
Roche opens €90m gene therapy development centre
/in News/by Thomas GabrielczykBasel-headquartered Roche AG has inaugurated a brand new €90m gene therapy development centre in Penzberg near Munich. <br /><br /><br />
AstraZeneca to take over Fusion Therapeutics Inc
/in News/by Thomas GabrielczykBritish pharma giant AstraZeneca has announced to acquire radio-conjugate specialist Fusion Therapeutics Inc for US$2bn upfront.
Senisca Ltd raises £3.7m seed money
/in News/by Thomas GabrielczykExeter-based university spin-out Senisca Ltd has added £3.7m seed money to a £1.1m not dilutive funding to advance its pipeline of drugs targetting RNA splicing dysregulation.
AstraZeneca to acquire Amolyt Pharma for up to US$1.05bn
/in News/by Thomas GabrielczykFrench endocrine diseases specialist Amolyt Pharma SA has entered into a take-over agreement by AstraZeneca.
Relation Therapeutics Ltd bags US$35m in seed financing.
/in News/by Thomas GabrielczykLondon-based virtual drug discovery specialist Relation Therapeutics Ltd has closed another US$35m seed financing round, bringing its total seed fundraise to US$60m.
Researcher find potential target for atherosclerosis
/in News/by Thomas GabrielczykTREM2, a receptor on the surface of macrophages, reduces necrotic core formation in early atherosclerosis, a German-Austrian reseach team reports.
Obesity: Arecor Therapeutics partners with TRx Biosciences
/in News/by Thomas GabrielczykBritish companies Arecor Therapeutics plc and TRx Biosciences Ltd combine their technologies to formulate an oral GLP-1 receptor agonist with enhanced bioavailability<br />